Shire PLC (SHPG) Holdings Cut by Catalyst Capital Advisors LLC  Stephan Jacobs | Aug 17th, 2018
Catalyst Capital Advisors LLC lowered its stake in shares of Shire PLC (NASDAQ:SHPG) by 57.0% during the second quarter, Holdings Channel reports. The institutional investor owned 709 shares of the biopharmaceutical company's stock after selling 940 shares during the quarter. Catalyst Capital Advisors LLC's holdings in Shire were worth $119,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of SHPG. Rockefeller Capital Management L.P. bought a new position in shares of Shire during the 1st quarter valued at about $113,097,000. Mizuho Securities USA LLC bought a new position in shares of Shire during the 2nd quarter valued at about $338,000. Creative Planning lifted its holdings in shares of Shire by 14.3% during the 2nd quarter. Creative Planning now owns 6,555 shares of the biopharmaceutical company's stock valued at $1,106,000 after purchasing an additional 818 shares in the last quarter. Pitcairn Co. lifted its holdings in shares of Shire by 280.3% during the 1st quarter. Pitcairn Co. now owns 7,054 shares of the biopharmaceutical company's stock valued at $1,054,000 after purchasing an additional 5,199 shares in the last quarter. Finally, Gateway Investment Advisers LLC bought a new position in shares of Shire during the 2nd quarter valued at about $9,563,000. Hedge funds and other institutional investors own 17.61% of the company's stock. Get Shire alerts:
Several equities analysts have recently weighed in on SHPG shares. Kepler Capital Markets reiterated a "buy" rating on shares of Shire in a report on Friday, May 11th. Royal Bank of Canada reiterated a "buy" rating on shares of Shire in a report on Tuesday, May 8th. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the company a "buy" rating in a report on Tuesday, July 31st. B. Riley lifted their price objective on Shire to $200.00 and gave the company a "buy" rating in a report on Thursday, April 19th. Finally, BTIG Research reiterated a "buy" rating and set a $195.00 price objective on shares of Shire in a report on Sunday, April 29th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company's stock. Shire presently has an average rating of "Buy" and an average price target of $201.18.
Shares of Shire stock opened at $171.50 on Friday. Shire PLC has a 52-week low of $123.73 and a 52-week high of $177.51. The company has a market capitalization of $52.16 billion, a P/E ratio of 11.32, a PEG ratio of 1.52 and a beta of 1.19. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.45.
Shire (NASDAQ:SHPG) last announced its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $3.67 by $0.21. Shire had a return on equity of 13.22% and a net margin of 31.06%. The business had revenue of $3.92 billion for the quarter. During the same period in the prior year, the business posted $3.73 EPS. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. research analysts forecast that Shire PLC will post 15.29 earnings per share for the current year.
About Shire
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Read More: Growth Stocks, What They Are, What They Are Not
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG). Shire Shir